Merck's Q3 results indicated strong execution with an 11% non-GAAP EPS increase, driven by solid in-line portfolio performance countered by some challenges like patent expiries and regulatory environment changes. However, specific comments from the management like ongoing restructuring, concerns on future pricing pressures, and lower R&D spending suggest a potential cautious outlook which might limit the stock's short-term performance. The evolving U.S. health care reform landscape adds uncertainty, impacting long-term profitability. 
[1]
        